Health Care & Life Sciences » Biotechnology | Biocartis Group

Biocartis Group N.V. | Mutual Funds

Mutual Funds that own Biocartis Group N.V.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
C+F Vega Equity
957,405
1.87%
221,405
1.54%
06/29/2018
Universal Invest Medium
622,000
1.21%
0
0.17%
06/30/2018
C+F Belgian Growth
505,000
0.98%
56,150
3.6%
06/29/2018
Pricos
374,540
0.73%
9,617
0.1%
12/31/2017
C+F Euro Equities
322,309
0.63%
72,309
0.9%
06/29/2018
Universal Invest High
311,000
0.61%
0
0.21%
06/30/2018
LBPAM Actions Mid Cap
254,387
0.5%
0
1.14%
06/29/2018
247,900
0.48%
222,900
0.67%
12/31/2017
BNP Paribas B - Pension Balanced
216,642
0.42%
0
0.08%
09/29/2017
BL - European Smaller Companies
214,600
0.42%
0
1.07%
07/31/2018

About Biocartis Group

View Profile
Address
Generaal de Wittelaan 11 B3
Mechelen VL 2800
Belgium
Employees -
Website http://www.biocartis.com
Updated 07/08/2019
Biocartis Group NV is a commercial stage molecular diagnostics company, which engaegs in the provision of diagnostic solutions. It operates through MDx Idylla™ platform, an automated sample-to-result, real-time polymerase chain reaction system that offers molecular information from virtually any biological sample. The company was founded by Renaud Philippe, Nader Donzel, and Rudi Pauwels in July 2007 and is headquartered in Mechelen, Belgium.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.